PH12014501601A1 - Artemisinin-based combination therapy for treating viral mediated disease - Google Patents

Artemisinin-based combination therapy for treating viral mediated disease

Info

Publication number
PH12014501601A1
PH12014501601A1 PH12014501601A PH12014501601A PH12014501601A1 PH 12014501601 A1 PH12014501601 A1 PH 12014501601A1 PH 12014501601 A PH12014501601 A PH 12014501601A PH 12014501601 A PH12014501601 A PH 12014501601A PH 12014501601 A1 PH12014501601 A1 PH 12014501601A1
Authority
PH
Philippines
Prior art keywords
artemisinin
combination therapy
individual
effective amount
act
Prior art date
Application number
PH12014501601A
Inventor
Steele Robert Lewis
Musso Anthony Fedele
David D Mundschenk
De Casteele Van Russell
Original Assignee
Kryptonite Group Ltd
Steele Robert Lewis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/201,749 external-priority patent/US20140256762A1/en
Application filed by Kryptonite Group Ltd, Steele Robert Lewis filed Critical Kryptonite Group Ltd
Publication of PH12014501601A1 publication Critical patent/PH12014501601A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention describes a method of treating individuals suffering from microbial infections, including a viral infection such as Dengue Fever, using an improved Artemisinin Combination Therapy (ACT), known as Tri-ACT. The improved ACT therapy includes administering a combination of three drugs. In one embodiment of the present invention, the method includes administering to an individual a first composition comprising a therapeutically effective amount of an artemether spray sublingually. The individual is then administered a second compositions, a therapeutically effective amount of artesunate. A third compositon, an effective amount of berberine, or its pharmaceutically acceptable derivatives or salts is then administered to the individual.
PH12014501601A 2013-09-17 2014-07-11 Artemisinin-based combination therapy for treating viral mediated disease PH12014501601A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361878848P 2013-09-17 2013-09-17
US14/201,749 US20140256762A1 (en) 2012-07-06 2014-03-07 Artemisinin-based combination therapy for treating viral mediated disease
PCT/US2014/033556 WO2015041723A1 (en) 2013-09-17 2014-04-09 Artemisinin-based combination therapy for treating viral mediated disease

Publications (1)

Publication Number Publication Date
PH12014501601A1 true PH12014501601A1 (en) 2015-09-14

Family

ID=50928251

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12014501601A PH12014501601A1 (en) 2013-09-17 2014-07-11 Artemisinin-based combination therapy for treating viral mediated disease

Country Status (2)

Country Link
PH (1) PH12014501601A1 (en)
WO (2) WO2015041723A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2722981C1 (en) * 2019-12-31 2020-06-05 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) (ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Се Method of treating malaria using a therapeutic combination of telomerase inhibitors (iimatinib mesilate) and artemether
WO2021162394A1 (en) 2020-02-14 2021-08-19 충북대학교 산학협력단 Chimeric antigen receptor targeting b-cell maturation antigen and use thereof
WO2022128920A2 (en) * 2020-12-14 2022-06-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of drugs that stiffen mature gametocytes for blocking transmission of plasmodium parasites

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225427A (en) 1988-10-04 1993-07-06 Hoechst Aktiengesellschaft 10-substituted ether derivatives of dihydroartemisinin, process for their preparation and their use as antiprotozoal agents
US5225562A (en) 1990-08-10 1993-07-06 Mcchesney James D Method of preparing (+)-deoxoartemisinin and selected analogues of (+)-deoxoartemisinin
USRE38117E1 (en) 1995-06-29 2003-05-06 Hauser, Inc. Trioxane dimer compound having antiproliferative and antitumor activities
US5677468A (en) 1995-06-29 1997-10-14 Hauser, Inc. Artemisinin dimer compounds having anticancer activity
US6136847A (en) 1996-12-02 2000-10-24 Johns Hopkins University Water-soluble trioxanes as potent and safe antimalarial agents
CH692321A5 (en) 1997-11-03 2002-05-15 Mepha Ag Pharmaceutically effective composition which comprises an effective anti-malarial parasite substance.
US6160004A (en) 1997-12-30 2000-12-12 Hauser, Inc. C-10 carbon-substituted artemisinin-like trioxane compounds having antimalarial, antiproliferative and antitumor activities
US6127405A (en) 1998-07-10 2000-10-03 Council Of Scientific And Industrial Research Method for the use of alpha arteether as an anti-bacterial and anti-fungal agent
SI1095042T1 (en) 1998-07-14 2006-04-30 Bayer Healthcare Ag Antiparasitic artemisinin derivatives (endoperoxides)
US6649647B1 (en) 1998-07-14 2003-11-18 Richard Haynes Trioxane derivatives
US6126038A (en) 1998-10-30 2000-10-03 Olegnowicz; Israel Atomizing pump spray
AU2001257577A1 (en) 2000-02-28 2001-09-03 Shearwater Corporation Water-soluble polymer conjugates of artelinic acid
DE10014669C1 (en) 2000-03-24 2002-05-23 Council Scient Ind Res Preparation of arteether, useful for treating malaria comprises dissolving dihydroartemisinin in ethanol, adding solid acid catalyst with trialkylorthoformate and extracting with a non-polar organic solvent
WO2003068736A2 (en) 2002-02-09 2003-08-21 U.S. Army Medical Research And Material Command Mixed steroidal 1,2,4,5-tetraoxane compounds and methods of making and using thereof
US6861066B2 (en) 2002-03-11 2005-03-01 Health Plus International Inc. Method for the delivery of a biologically active agent
US6683193B2 (en) 2002-03-25 2004-01-27 Council Of Scientific And Industrial Research Single pot conversion of artemisinin into artemether
US6685972B2 (en) 2002-03-25 2004-02-03 Council Of Scientific And Industrial Research Process for isolating artemisinin from Artemisia annua
US6737438B2 (en) 2002-03-28 2004-05-18 Council Of Scientific And Industrial Research Substituted 1,2,4-trioxanes useful as antimalarial agents and a process for the preparation thereof
US6906205B2 (en) 2002-06-21 2005-06-14 Medicines For Malaria Venture Mmv Spiro and dispiro 1,2,4-trioxolane antimalarials
US6790863B2 (en) 2002-10-15 2004-09-14 University Of Mississippi Dihydroartemisinin and dihydroartemisitene dimers as anti-cancer and anti-infective agents
US6750356B1 (en) 2002-12-02 2004-06-15 Council Of Scientific And Industrial Research Single pot conversion of artemisinin into arteether
WO2005023304A2 (en) * 2003-09-04 2005-03-17 Cipla Limited Antimalarial compositions and manufacturing process thereof
US7071226B1 (en) 2004-12-28 2006-07-04 Council Of Scientific And Industrial Research Amino-functionalized 1,2,4-trioxanes useful as antimalarial agents and process for preparation thereof
US20140011830A1 (en) * 2012-07-06 2014-01-09 Robert Lewis Steele Artemisinin-Based Combination Therapy For Treating Parasitic Mediated Disease
US20130071474A1 (en) * 2009-04-22 2013-03-21 James Spencer COMBINATIONS OF BERBERINE, ARTEMISININ, Loperamide AND THEIR DERIVATIVES TO TREAT MALARIA, DIARRHEA, TRAVELERS' DIARRHEA, DYSENTERY, DENGUE FEVER, PARASITES, CHOLERA AND VIRUSES
EP2770985A4 (en) * 2011-10-25 2015-01-21 U S Phytotherapy Inc Artemisinin and berberine compositions and methods of making
US20140011829A1 (en) * 2012-07-06 2014-01-09 Robert Lewis Steele Artemisinin-Based Combination Therapy For Treating Viral Mediated Disease

Also Published As

Publication number Publication date
WO2015041723A1 (en) 2015-03-26
WO2015041722A1 (en) 2015-03-26

Similar Documents

Publication Publication Date Title
CY1120429T1 (en) KINAZOLIN DERIVATIVE FOR THE THERAPEUTIC TREATMENT OF VIRUS INFECTIONS AND OTHER DISEASES
AU2018256602A1 (en) Functionalized benzamide derivatives as antiviral agents against hbv infection
CY1119490T1 (en) PYRAZOLOPYROLIDINE PRODUCTS AND THEIR USE IN PATIENT TREATMENT
WO2009123776A3 (en) Antiviral drugs for treatment of arenavirus infection
EA201592256A1 (en) DERIVATIVES OF IMIDAZOPIRROLIDINONE AND THEIR APPLICATION IN THE TREATMENT OF DISEASES
EA201590343A1 (en) ALKYLPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES
WO2013123215A3 (en) Antiviral drugs for treatment of arenavirus infection
DOP2011000343A (en) PIRIDINE TIENO DERIVATIVES [2,3-B] AS VIRAL REPLICATION INHIBITORS
EA202090258A2 (en) PYRROLO [3,2-d] PYRIMIDINE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS AND OTHER DISEASES
EA201490254A1 (en) COMBINED TREATMENT OF HEPATITIS C
PH12015500713A1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
NZ709260A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EA201591363A1 (en) TIADIAZOLE ANALOGUES AND METHODS OF TREATMENT OF STATES ASSOCIATED WITH SMN DEFICIENCY
BR112015029401A8 (en) pyrazolo-pyrrolidin-4-one derivatives, their uses, and pharmaceutical composition and combination
BR112015013695A2 (en) pharmaceutical composition and methods for treating and preventing an HIV infection
EA201491479A1 (en) DERIVATIVES OF LUPANOV TRITERPENOIDS AND THEIR PHARMACEUTICAL APPLICATIONS
EA201890507A1 (en) COMBINATION OF ANTI-VIRAL DIRECT ACTION AND RIBAVIRIN FOR THE TREATMENT OF PATIENTS WITH HCV
MX2013003635A (en) N-heteroaryl compounds.
BR112019007863A2 (en) innovative naphthyridinone derivatives and their use in the treatment of arrhythmia
PH12014501601A1 (en) Artemisinin-based combination therapy for treating viral mediated disease
BR112022000971A2 (en) Dihydropyrimidine derivatives and their use in the treatment of hbv infection or hbv-induced diseases
EA201592242A1 (en) PYRIDON DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER DISEASES
IN2013CH05288A (en)
PH12014501600A1 (en) Enhanced artemisinin-based combination therapy for treating parasitic mediated disease
EA201491652A1 (en) MEANS FOR TREATING VIRAL HEPATITIS C